MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

The first sa-mRNA vaccine to reach any market was Gennova Biopharmaceuticals' Gemcovac, which was launched in India in 2022 ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

Laura is an editor and staff writer at IFLScience. She obtained her Master's in Experimental Neuroscience from Imperial College London.

Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property – is also testing a vaccine that combines COVID-19 and flu in a single jab in a ...

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

Thai prosecutors on Friday formally indicted a fugitive 86-year-old healthcare tycoon for loan fraud worth $480 million, ...

Cambridge, Massachusetts – home to Harvard and MIT – was the primary source of Chinese researchers who chose to head home.

Pfizer’s contributions to animal health date back several decades, during which the company played a significant role in ...

The discovery has shed light on a complex blood interaction that has likely always been present in humans but was unnoticed ...

The Senate has voted to confirm the nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services. Publicly traded ...